Carboplatin

Carboplatin
Clinical data
Pronunciation	/ˈkɑːrboʊˌplætən/
Trade names	Paraplatin, others
AHFS/Drugs.com	Monograph
MedlinePlus	a695017
Routes of; administration	Intravenous
ATC code	L01XA02 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: WARNING; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	complete
Protein binding	Very low
Elimination half-life	1.1-2 hours
Excretion	Kidney
Identifiers
	IUPAC name cis-diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II);
CAS Number	41575-94-4 ;
PubChem CID	498142;
DrugBank	DB00958 ;
ChemSpider	8514637 ;
UNII	BG3F62OND5;
KEGG	D01363 ;
ChEBI	CHEBI:31355 ;
ChEMBL	ChEMBL288376 ;
CompTox Dashboard (EPA)	DTXSID3046742 ;
ECHA InfoCard	100.050.388
Chemical and physical data
Formula	C6H12N2O4Pt
Molar mass	371.256 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC2(C1)C(=O)O[Pt-2]([NH3+])([NH3+])OC2=O;
	InChI InChI=1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2 ; Key:OLESAACUTLOWQZ-UHFFFAOYSA-L ;
	(what is this?) (verify)

Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.^[3] This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma.^[3] It is used by injection into a vein.^[3]

Side effects generally occur.^[3] Common side effects include low blood cell levels, nausea, and electrolyte problems.^[4]^[3] Other serious side effects include allergic reactions and mutagenesis. It may be carcinogenic, but further research is needed to confirm this.^[3] Use during pregnancy may result in harm to the baby.^[3] Carboplatin is in the platinum-based antineoplastic family of medications and works by interfering with duplication of DNA.^[3]^[5]

Carboplatin was developed as a less toxic analogue of cisplatin.^[6] It was patented in 1972 and approved for medical use in 1989.^[7] It is on the 2023 World Health Organization's List of Essential Medicines.^[8]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
^ ^a ^b ^c ^d ^e ^f ^g ^h "Carboplatin". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
^ Oun R, Moussa YE, Wheate NJ (May 2018). "The side effects of platinum-based chemotherapy drugs: a review for chemists". Dalton Transactions. 47 (19): 6645–6653. doi:10.1039/c8dt00838h. PMID 29632935.
^ Apps MG, Choi EH, Wheate NJ (August 2015). "The state-of-play and future of platinum drugs". Endocrine-Related Cancer. 22 (4): R219–R233. doi:10.1530/ERC-15-0237. hdl:2123/24426. PMID 26113607.
^ Cite error: The named reference lebwohl was invoked but never defined (see the help page).
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 513. ISBN 9783527607495. Archived from the original on 2016-12-20.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.